Cargando…
Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer
BACKGROUND: Despite the rapid adoption of immunotherapies in advanced non–small cell lung cancer (advNSCLC), knowledge gaps remain about their real‐world (rw) performance. METHODS: This retrospective, observational, multicenter analysis used the Flatiron Health deidentified electronic health record‐...
Autores principales: | Khozin, Sean, Miksad, Rebecca A., Adami, Johan, Boyd, Mariel, Brown, Nicholas R., Gossai, Anala, Kaganman, Irene, Kuk, Deborah, Rockland, Jillian M., Pazdur, Richard, Torres, Aracelis Z., Zhi, Jizu, Abernethy, Amy P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899461/ https://www.ncbi.nlm.nih.gov/pubmed/31381142 http://dx.doi.org/10.1002/cncr.32383 |
Ejemplares similares
-
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer
por: Stewart, Mark, et al.
Publicado: (2019) -
Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States
por: Zhang, Qianyi, et al.
Publicado: (2021) -
An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records database
por: Carrigan, Gillis, et al.
Publicado: (2019) -
Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data Quality
por: Miksad, Rebecca A., et al.
Publicado: (2017) -
Developing and adopting safe and effective digital biomarkers to improve patient outcomes
por: Coravos, Andrea, et al.
Publicado: (2019)